EUVIMEDEUVIMED entdecken
Crossref

First-line FOLFOXIRI-based Chemotherapy for Unresectable Metastatic Colorectal Cancer: Real-world Outcomes, Safety, and Conversion Surgery

Akira Inoue, Hirofumi Ota, Yusuke Matsuura, Koji Munakata, Masataka Fujiwara, Kosuke Nishihara, Ryutaro Wada, Ryohei Wada, Y U Takeda, Sakae Maeda, Kou Takachi

Anticancer Research · 2026

DOI: 10.21873/anticanres.18003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Akira Inoue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Ikeda City Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Camptothecin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: In Japan, contemporary real-world data that simultaneously assess effectiveness, safety, conversion feasibility, and long-term outcomes of first-line FOLFOXIRI-based chemotherapy for unresectable metastatic colorectal cancer (mCRC) remain limited. Here, we aimed to evaluate the real-world efficacy, safety, and long-term outcomes of this treatment as well as to identify factors associated with conversion surgery. PATIENTS AND METHODS: We conducted a retrospective single-center cohort study of consecutive patients with first-line FOLFOXIRI (±targeted agent). Progression-free survival (PFS) encompassed the entire first-line treatment period. Survival outcomes were analyzed using Kaplan-Meier and log-rank tests, with hazard ratios (HRs) estimated by Cox models. Adverse events (AEs) were graded according to CTCAE v5.0. RESULTS: Of 59 patients (median FOLFOXIRI cycles: 7), bevacizumab was administered to 74.6%. The objective response rate was 66.1% and the disease control rate was 88.1%. Conversion surgery was achieved in 27.1% of patients, with R0 resection in 23.7% of the cohort. Patients undergoing conversion surgery had longer PFS and overall survival (OS) than those who did not. Conversion was associated with rectal primaries and the absence of peritoneal metastasis. In RAS-stratified analyses, PFS was similar, whereas OS was shorter in RAS-mutant tumors. Grade ≥3 neutropenia and febrile neutropenia occurred in 72.9% and 25.4% of patients, respectively; severe non-hematological AEs were rare, and no treatment-related deaths occurred. CONCLUSION: In Japanese practice, first-line FOLFOXIRI achieved substantial disease control and clinically meaningful survival with manageable toxicity. R0 conversion was achieved in the subset with longer survival. A conversion-oriented triplet induction strategy may be considered for rectal cancer without peritoneal metastasis, irrespective of RAS status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCamptothecinHumansFluorouracilLeucovorinFemaleOrganoplatinum CompoundsMaleAgedMiddle AgedRetrospective StudiesTreatment OutcomeAdultNeoplasm MetastasisBevacizumabProgression-Free Survival

Stichwörter der Autor:innen

FOLFOXIRIclinical outcomesconversion surgeryunresectable metastatic colorectal cancer

Substanzen

FluorouracilLeucovorinOrganoplatinum CompoundsCamptothecinBevacizumab

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Ikeda City Hospital, Osaka, Japan.
  • Department of Gastroenterological Surgery, Ikeda City Hospital, Osaka, Japan hirootajp@yahoo.co.jp.

Zitieren

APA

Inoue, A., Ota, H., Matsuura, Y., Munakata, K., Fujiwara, M., Nishihara, K., Wada, R., Wada, R., Takeda, Y. U., Maeda, S., & Takachi, K. (2026). First-line FOLFOXIRI-based Chemotherapy for Unresectable Metastatic Colorectal Cancer: Real-world Outcomes, Safety, and Conversion Surgery. Anticancer Research. https://doi.org/10.21873/anticanres.18003

Vancouver

Inoue A, Ota H, Matsuura Y, Munakata K, Fujiwara M, Nishihara K, et al. First-line FOLFOXIRI-based Chemotherapy for Unresectable Metastatic Colorectal Cancer: Real-world Outcomes, Safety, and Conversion Surgery. Anticancer Research. 2026. doi:10.21873/anticanres.18003

BibTeX
@article{Inoue2026,
  author = {Inoue, Akira and Ota, Hirofumi and Matsuura, Yusuke and Munakata, Koji and Fujiwara, Masataka and Nishihara, Kosuke and Wada, Ryutaro and Wada, Ryohei and Takeda, Y U and Maeda, Sakae and Takachi, Kou},
  title = {First-line FOLFOXIRI-based Chemotherapy for Unresectable Metastatic Colorectal Cancer: Real-world Outcomes, Safety, and Conversion Surgery},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18003}
}
Kostenlos starten →